ALKS

28.62

0.63% 0.18

Vorhandelsmarkt: 28.63 0.010 +0.03%

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$28.44

Offen:

$28.52

24-Stunden-Volumen:

2.21M

Relative Volume:

0.93

Marktkapitalisierung:

$4.73B

Einnahmen:

$1.51B

Nettoeinkommen (Verlust:

$333.35M

KGV:

14.68

EPS:

1.95

Netto-Cashflow:

$315.22M

1W Leistung:

-3.08%

1M Leistung:

-12.34%

6M Leistung:

-7.86%

1J Leistung:

-6.47%

1-Tages-Spanne:

$27.80

$28.77

1-Wochen-Bereich:

$27.80

$29.80

52-Wochen-Spanne:

$25.16

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1124)

Branche

Drug Manufacturers - Specialty & Generic (85)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

1,800

Twitter

@alkermes

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Vergleichen Sie ALKS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	28.62	4.70B	1.51B	333.35M	315.22M	1.95
ZTS Zoetis Inc	118.07	51.01B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.37	45.05B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.46	41.46B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.80	32.77B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	484.86	20.51B	3.08B	1.24B	1.07B	25.61

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-11	Eingeleitet	Truist	Buy
2025-09-26	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Eingeleitet	Wells Fargo	Overweight
2025-07-15	Eingeleitet	Goldman	Buy
2025-06-17	Hochstufung	UBS	Neutral → Buy
2025-05-28	Eingeleitet	Needham	Buy
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-03-04	Hochstufung	UBS	Sell → Neutral
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

Dec 09, 2025

(ALKS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com

Dec 07, 2025

Dec 06, 2025

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid - MSN

Dec 06, 2025

Dec 05, 2025

Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN

Dec 05, 2025

Avadel Pharmaceuticals plc and Alkermes plc Announce Proposed Transaction for Acquisition - Quiver Quantitative

Dec 05, 2025

Announcement relating to despatch of Rule 15 proposal - The Manila Times

Dec 05, 2025

Avadel (NASDAQ: AVDL) sends Rule 15 proposal to equity holders in Alkermes deal - Stock Titan

Dec 05, 2025

Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS - MarketBeat

Dec 05, 2025

Dec 04, 2025

Will Alkermes plc (8AK) stock sustain bullish trend into 2025Fed Meeting & Smart Money Movement Tracker - Newser

Dec 04, 2025

ALKS: Elixirxton demonstrates strong efficacy, safety, and dosing flexibility for narcolepsy and hypersomnolence - TradingView

Dec 04, 2025

Dec 03, 2025

Avadel Pharmaceuticals Announces Mailing of Definitive Proxy Statement Regarding Proposed Acquisition by Alkermes - Quiver Quantitative

Dec 03, 2025

Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting - Benzinga

Dec 03, 2025

Avadel (Nasdaq: AVDL) mails proxy, sets Jan. 12 scheme and EGM on Alkermes deal - Stock Titan

Dec 03, 2025

VP Hopkinson Files To Sell 3,748 Of Alkermes PLC [ALKS] - TradingView

Dec 03, 2025

Mackenzie Financial Corp Acquires 53,323 Shares of Alkermes plc $ALKS - MarketBeat

Dec 03, 2025

Evercore Healthcare Conference - marketscreener.com

Dec 03, 2025

How Alkermes plc (8AK) stock valuation compares with sectorQuarterly Profit Report & Daily Profit Focused Screening - Newser

Dec 03, 2025

Is Alkermes plc (8AK) stock a safe buy pre earningsMarket Growth Summary & Real-Time Sentiment Analysis - Newser

Dec 03, 2025

Dec 02, 2025

Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 4,000 Shares of Stock - MarketBeat

Dec 02, 2025

Regeneron, Tessera to advance gene editing therapy for AATD: Deals Report - BioCentury

Dec 02, 2025

How supply chain issues affect Alkermes plc stockPortfolio Performance Report & Real-Time Stock Movement Alerts - Newser

Dec 02, 2025

Should Alkermes (ALKS) Investors Reassess Prospects After Raised 2025 Guidance and Strong Q3 Results? - Yahoo Finance

Dec 02, 2025

Is Alkermes plc (8AK) stock among top earnings playsQuarterly Trade Review & Real-Time Volume Surge Alerts - Newser

Dec 02, 2025

Dec 01, 2025

Insider Sell: Craig Hopkinson Sells 4,000 Shares of Alkermes PLC (ALKS) - GuruFocus

Dec 01, 2025

Alkermes plc. Officer Sells 4,000 Shares - TradingView

Dec 01, 2025

VP Hopkinson Sells 4,000 ($117.2K) Of Alkermes PLC [ALKS] - TradingView

Dec 01, 2025

Avadel Pharmaceuticals plc Announces Scheme Meeting for Alkermes Acquisition Proposal - Quiver Quantitative

Dec 01, 2025

Avadel Pharmaceuticals (Nasdaq: AVDL) to hold Scheme and EGM on Alkermes takeover Jan. 12 - Stock Titan

Dec 01, 2025

Rhumbline Advisers Purchases 17,660 Shares of Alkermes plc $ALKS - MarketBeat

Dec 01, 2025

Legal & General Group Plc Sells 17,227 Shares of Alkermes plc $ALKS - MarketBeat

Dec 01, 2025

Nov 30, 2025

Loomis Sayles & Co. L P Sells 330,389 Shares of Alkermes plc $ALKS - MarketBeat

Nov 30, 2025

Nov 28, 2025

JPMorgan Chase & Co. Trims Stock Position in Alkermes plc $ALKS - MarketBeat

Nov 28, 2025